<DOC>
	<DOCNO>NCT00554853</DOCNO>
	<brief_summary>Patients rheumatoid arthritis significantly high risk develop heart attack complication blood vessel . New therapy need prevent complication . The purpose study establish role medication pioglitazone improve function blood vessel heart decrease risk future atherosclerosis development individual rheumatoid arthritis . As secondary aim-point , evaluate efficacy pioglitazone improve rheumatoid arthritis disease activity marker inflammation .</brief_summary>
	<brief_title>PPAR-gamma Agonists , Rheumatoid Arthritis Cardiovascular Disease</brief_title>
	<detailed_description>This study establish role pioglitazone improvement endothelial function , arterial compliance disease activity patient rheumatoid arthritis . This placebo-controlled , double blind , cross-over trial . Two measure initially list separate outcome measure : ( Decrease inflammation ) Efficacy pioglitazone improve rheumatoid arthritis disease activity marker inflammation show combine score ( DAS-28-CRP ) . The Risks Side Effects outcome measure would duplicative table adverse event section therefore delete outcome measure .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Nitroglycerin</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Women adequate contraception childbearing age . Meet revise ACR criterion RA . Stable dos DMARDS , biologic agent corticosteroid least 3 month . Pregnant lactating woman . Current smoker individual smoke last 6 month . Diagnosis Diabetes , heart failure , infection . Current diagnosis malignant disease except basal cell squamous cell carcinoma skin . No active liver disease . No cholesterollowering medication oral hypoglycemic agent .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>